On February 12, 2025, Chihealbio Group held the 2025 Annual Work Mobilization Meeting at the beginning of the New Year. Dr. Zhang Zhefeng, Chairman of the Group, Mr. Hou Junqi, Vice President of Operations, Ms. Hou Wen, Vice President of the Group, along with middle management from various subsidiaries, participated in the meeting.

This meeting presented a comprehensive plan and outlook for the Group's development in the new year, providing clear direction for all employees and sounding the horn for the new year's progress.

At the beginning of the meeting, Dr. Zhang Zhefeng, Chairman of the Group, delivered an important speech. He started by providing an in-depth analysis of the current market and industry environment, pointing out that the pharmaceutical industry is at a critical stage of transformation and upgrading, with both opportunities and challenges. Dr. Zhang emphasized that the achievements of Chiheal Group in the field of innovative drug development are commendable, and in the future, the Group must continue to increase investment in R&D, enhance independent innovation capabilities, and use innovative drugs as the core competitive advantage to drive high-quality development.

In terms of market expansion, Dr. Zhang Zhefeng emphasized the need to vigorously expand the business market, especially the international business market, and seize new market opportunities to open up international markets. He pointed out that the international market holds tremendous potential, and Chihealbio Group should seize opportunities such as the "Belt and Road" initiative to actively explore overseas markets and enhance the Group’s international influence.

Driving Innovation through AI Technology

Dr. Zhang Zhefeng highlighted the immense potential of AI in pharmaceutical R&D: accelerating drug discovery and design, overcoming clinical trial efficiency bottlenecks, and analyzing and managing pharmaceutical R&D data. In response to the new trends in artificial intelligence development, the company will increase its investment in applying AI technology at all stages of drug development. The integration of AI will bring unprecedented improvements in efficiency and innovation breakthroughs to the company’s pharmaceutical R&D, potentially accelerating the drug development process and having significant strategic implications for the company’s future development.

Mr. Hou Junqi, Vice President of Operations, provided a detailed introduction to the new Group organizational structure for 2025. The new structure places greater emphasis on collaboration and resource integration, with the aim of improving the overall operational efficiency of the Group. It will break down departmental barriers and establish a cross-departmental and cross-regional collaborative work mechanism, ensuring smoother information flow and more efficient decision-making execution. Mr. Hou emphasized that by optimizing the organizational structure, the Group will be better equipped to adapt to market changes, respond quickly to customer needs, and enhance its market competitiveness.

Clarify Goals and Give Our Best Effort

Following this, Mr. Hou Junqi, Vice President of Operations, and Ms. Hou Wen, Vice President of the Group, outlined the goal deployment and planning for each subsidiary and business unit. They elaborated on the specific tasks and objectives for each subsidiary and business unit in 2025, requiring each department to clarify responsibilities and break down the goals into detailed, actionable steps. Subsidiaries and business units are expected to adjust strategies flexibly in response to market changes, ensuring the achievement of annual goals. Additionally, they emphasized the importance of strengthening team building, enhancing employees' professional skills and overall qualities, and providing solid talent support for the Group's development.

A New Journey Begins, Together Advancing into a New Era of Pharmaceuticals

2025 is a year full of opportunities and challenges. Chihealbio Group will take this work mobilization meeting as an opportunity to embark on a new journey and jointly build the future of pharmaceutical innovation. Let us move forward together, driven by innovation, supported by talent, and guided by the market, continuously advancing the development and growth of the Group, and contributing more to the progress of the pharmaceutical industry.

All members of Chihealbio Group will embrace every challenge of 2025 with even greater enthusiasm and determination, creating even more brilliant achievements!